Treatment of Multiple Sclerosis using Over the Counter Inosine
This study is currently recruiting patients.
Purpose
The purpose of this study is to determine whether raising low levels of the natural antioxidant uric acid by the administration
of a precursor, inosine, has any therapeutic effect on the progression of Relapsing Remitting Multiple Sclerosis (RRMS) and
secondary progressive Multiple Sclerosis (MS).
Condition
|
Treatment or Intervention |
Phase |
Multiple Sclerosis, Relapsing-Remitting
|
Drug: Inosine
|
Phase II
|
MedlinePlus related topics: Multiple Sclerosis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Further Study Details:
Expected Total Enrollment:
30
Study start: February 2002;
Study completion: December 2004
Uric acid is a natural inhibitor of certain chemistries associated with peroxynitrite, a product of inflammation. In animal
models of multiple sclerosis (MS), these chemical reactions have been associated with breakdown of the blood-brain barrier
and CNS tissue damage. In addition, MS patients have serum uric acid levels that are lower than age- and sex- matched healthy
individuals. The primary purpose of this study to determine whether raising low serum uric acid levels by daily oral administration
of its precursor inosine has an effect on the cumulative number of newly active lesions on magnetic resonance imaging (MRI)
and to evaluate the safety and tolerability of inosine in patients diagnosed with relapsing remitting and secondary progressive
MS.
Eligibility
Ages Eligible for Study:
18 Years
-
60 Years,
Genders Eligible for Study:
Both
Inclusion Criteria:
- Nonpregnant, nonlactating females
- Females of child bearing potential must have a negative human chorionic gonadotropin (HCG) test result within 60 days before
the first dose of study material.
- Males and females must practice adequate contraception, in the judgement of the investigator, during the course of the study.
- Subjects must have a diagnosis of clinically definite Relapsing Remitting Multiple Sclerosis based on medical history, physical
examination, laboratory test results, and neurologic examination. Alternatively, subjects may have clinically probable MS
characterized by 1 attack and the presence of at least 4 lesions on MRI within 12 months before the initial baseline evaluation.
- Subjects must have an Expanded Disability Status Scale (EDSS) test result of less than or equal to 5.0 within 60 days before
the first dose of study material.
- Subjects will have serum uric acid levels less than 5 mg/dl.
- Have 1 clinical relapse in the last year
Exclusion Criteria:
- Presence of any medical disability or laboratory test result that, in the judgement of the investigator, would interfere with
assessment of the tolerability, safety, or efficacy of study material or would compromise the subject's ability to provide
informed consent.
- Evidence of active infection characterized by requiring treatment with antibiotics within 7 days before the first dose of
study material.
- Treatment with interferons, glatiramer acetate, lymphoid irradiation, cyclophosphamide, or with other immune modifying treatments
within 3 months, or corticosteroids within 1 month before the initial baseline MRI assessment in this trial.
- Recent history (within the previous 2 years) of drug or alcohol abuse.
- Known allergy to Inosine products or history of anaphylaxis.
- Previous randomization into this study.
- Treatment with an investigational agent within 30 days before the first dose of study material.
Location
and Contact
Information
Pennsylvania Hospital of the University of Pennsylvania, Philadelphia,
Pennsylvania,
19104,
United States; Recruiting
Study chairs or principal investigators
Clyde E Markowitz, MD, Principal Investigator, University of Pennsylvania
Hilary Koprowski, MD, Study Director, Department of Microbiology and Immunology, Thomas Jefferson University
More Information
Click here for more information about the Inosine study.
Publications
Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, Koprowski H. Uric acid, a natural scavenger of peroxynitrite,
in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):675-80.
Hooper DC, Scott GS, Zborek A, Mikheeva T, Kean RB, Koprowski H, Spitsin SV. Uric acid, a peroxynitrite scavenger, inhibits
CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB
J. 2000 Apr;14(5):691-8.
Koprowski H, Spitsin SV, Hooper DC. Prospects for the treatment of multiple sclerosis by raising serum levels of uric acid,
a scavenger of peroxynitrite. Ann Neurol. 2001 Jan;49(1):139. No abstract available.
Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis
patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler. 2001
Oct;7(5):313-9.
Study ID Numbers:
R21 AT001301-01A1
Record last reviewed:
March 2004
Record first received:
August 15, 2003
ClinicalTrials.gov Identifier:
NCT00067327Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2004-11-10